University of Bergen Develops Technology for Potential Diarrhea Vaccine

By Simone Carter

Researchers from the University of Bergen (UiB) and NORCE have developed a new technology that could lead to a vaccine against enterotoxigenic Escherichia coli (ETEC), a significant global cause of severe diarrheal disease. This technology has been licensed to the international vaccine company Valneva, which will advance its development.

The licensed technology specifically targets the human heat-stable toxin (STh), a potent component of ETEC that has historically been challenging to address with vaccines. The licensing agreement, facilitated by Vestlandets Innovasjonsselskap (VIS), grants Valneva exclusive rights to commercialize the vaccine and outlines a pathway for its application in low- and middle-income countries.

This development builds on decades of research, with foundational work beginning in the 1980s and laboratory efforts initiated in 2009. The collaboration includes UiB, NORCE, Institut Pasteur, Indian Institute of Science, Tulane University, and South Dakota State University.

Stine Fiksdal, CEO of VIS, emphasized the importance of transitioning research from the laboratory to vaccine development, noting the agreement's support for access in underserved regions. Halvor Sommerfelt from UiB described the licensed technology as a milestone with potential for continued vaccine development.